Approval · Notice of Compliance 30648 · 2023
IBSRELA: Notice of Compliance 30648
Issued May 5, 2023
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 30648
- Date
- May 5, 2023
- Company
- Knight Therapeutics Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- To update the Product Monograph (PM) with new safety information and to convert the PM to the Master Template.
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| IBSRELA | Not yet assigned | — |
Medicinal ingredients
- TENAPANOR 53.2 MG per TAB